Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 245

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Leukotriene Antagonists as First-Line or Add-on Asthma-Controller Therapy

Open access
Price, David, Musgrave, Stanley D., Shepstone, Lee, Hillyer, Elizabeth V., Sims, Erika J., Gilbert, Richard F.T., Juniper, Elizabeth F., Ayres, Jon G., Kemp, Linda, Blyth, Annie, Wilson, Edward C.F., Wolfe, Stephanie, Freeman, Daryl, Mugford, H. Miranda, Murdoch, Jamie, Harvey, Ian·2011·New England Journal of Medicine

Abstract

BACKGROUND: Most randomized trials of treatment for asthma study highly selected patients under idealized conditions. METHODS: We conducted two parallel, multicenter, pragmatic trials to evaluate the real-world effectiveness of a leukotriene-receptor antagonist (LTRA) as compared with either an inhaled glucocorticoid for first-line asthma-controller therapy or a long-acting beta(2)-agonist (LABA) as add-on therapy in patients already receiving inhaled glucocorticoid therapy. Eligible primary care patients 12 to 80 years of age had impaired asthma-related quality of life (Mini Asthma Quality of Life Questionnaire [MiniAQLQ] score ≤6) or inadequate asthma control (Asthma Control Questionnaire [ACQ] score ≥1). We randomly assigned patients to 2 years of open-label therapy, under the care of their usual physician, with LTRA (148 patients) or an inhaled glucocorticoid (158 patients) in the first-line controller therapy trial and LTRA (170 patients) or LABA (182 patients) added to an inhaled glucocorticoid in the add-on therapy trial. RESULTS: Mean MiniAQLQ scores increased by 0.8 to 1.0 point over a period of 2 years in both trials. At 2 months, differences in the MiniAQLQ scores between the two treatment groups met our definition of equivalence (95% confidence interval [CI] for an adjusted mean difference, -0.3 to 0.3). At 2 years, mean MiniAQLQ scores approached equivalence, with an adjusted mean difference between treatment groups of -0.11 (95% CI, -0.35 to 0.13) in the first-line controller therapy trial and of -0.11 (95% CI, -0.32 to 0.11) in the add-on therapy trial. Exacerbation rates and ACQ scores did not differ significantly between the two groups. CONCLUSIONS: Study results at 2 months suggest that LTRA was equivalent to an inhaled glucocorticoid as first-line controller therapy and to LABA as add-on therapy for diverse primary care patients. Equivalence was not proved at 2 years. The interpretation of results of pragmatic research may be limited by the crossover between treatment groups and lack of a placebo group. (Funded by the National Coordinating Centre for Health Technology Assessment U.K. and others; Controlled Clinical Trials number, ISRCTN99132811.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1010846

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 245

Metadata

Authors
Price, D., Musgrave, S. D., Shepstone, L., Hillyer, E. V., Sims, E. J., Gilbert, R. F. T., Juniper, E. F., Ayres, J. G., Kemp, L., Blyth, A., Wilson, E. C. F., Wolfe, S., Freeman, D., Mugford, H. M., Murdoch, J., & Harvey, I.
Venue
New England Journal of Medicine
Published
2011-05-05
Volume
364
Issue
18
Pages
1695-1707
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2101864423
Cited by
245
References
5
FWCI
26.39
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Leukotriene Antagonists as First-Line or Add-on Asthma-Controller Therapy. https://app.cochat.ai/papers/10.1056/nejmoa1010846
The paper
Price, D., Musgrave, S. D., Shepstone, L., Hillyer, E. V., Sims, E. J., Gilbert, R. F. T., Juniper, E. F., Ayres, J. G., Kemp, L., Blyth, A., Wilson, E. C. F., Wolfe, S., Freeman, D., Mugford, H. M., Murdoch, J., & Harvey, I. (2011). Leukotriene Antagonists as First-Line or Add-on Asthma-Controller Therapy. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1010846

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.